Ruxolitinib performed better than best available therapy in the management of a cohort of patients with SR-aGVHD over a 24-month period. Published in the @ascopost.bsky.social journal Journal of Clinical Oncology. https://bit.ly/3XEBLuq #GVHD

Diagnostic delays for patients having symptoms of #VTE were associated with increased rates of all-cause mortality. Reported in @jamanetworkopen.com.#VTE https://bit.ly/44cOqZf

A secret shopper study in which researchers posed as AYAs with acute #lymphoblasticLeukemia trying to schedule an #oncology appointment has found that this population faces significant logistical burdens when accessing initial oncology care. From #ASCO25. https://bit.ly/4ib5gh0 #leusm #lymsm

When treated with ICIs, #cancerpatients with a pre-existing anxiety diagnosis appear to experience more irAEs and have better OS than those without anxiety. Published in @cancertherapyadv.bsky.social.#cancerpatients https://bit.ly/4894cqo

Researchers developed a new model to aid in individualized decision making around the use of prophylactic platelet transfusion in preterm infants who have severe #thrombocytopenia. Reported in @jama.com.#thrombocytopenia https://bit.ly/47KN1LX

Multiple studies have demonstrated variable incidence rates of #VTE across racial and ethnic groups in the United States. https://bit.ly/43LvCjR #HealthDisparities

Among patients with transplant-ineligible R/R #LBCL, combining mosunetuzumab with polatuzumab vedotin appears to reduce the risk of disease progression or death compared with R-GemOx. Published in @ascopost.bsky.social#LBCLJournal of Clinical Oncology. https://bit.ly/3WQSyKr #lymphoma #lymsm

In patients with severe #aplasticAnemia, upfront allogeneic HCT using alternative donors has become an option for some, but this method has had limited utilization. From @bloodjournals.hematology.org.#aplasticAnemia https://bit.ly/48bV1FK #anemia

Betty Pace, MD, of Augusta University talks about research to look forward to at the @ash.hematology.org meeting #ASH25. https://bit.ly/4p3Sjry #PedHeme #PedOnc

@ash.hematology.org President Belinda R. Avalos, MD, shares her perspectives on the past year’s political changes and how they are affecting #hematology research and care. https://bit.ly/474ugkS #HemOnc

Pretreatment blood signatures in patients with #DLBCL may indicate the likelihood of successful CAR T-cell therapy outcomes and could guide pretherapeutic approaches. Presented at #ESMO25. https://bit.ly/3Ll4MIU #lymsm #lymphoma

Unlike traditional #Medicare patients, Medicare Advantage enrollees who need major gen/gastro cancer surgery frequently use lower quality hospitals rather than high-quality teaching hospitals. @jamasurgery.com @renalurologynews.bsky.social.#Medicare https://bit.ly/4hLzJSA #gicsm #GCAM

Once-weekly subcutaneous marstacimab significantly reduced bleeding rates and was well tolerated in male patients with severe #hemophilia A or moderately severe to severe hemophilia B without inhibitors. Published in @bloodjournals.hematology.org#hemophilia https://bit.ly/47osaO7

In older cancer patients, receiving federal housing assistance is associated with earlier-stage diagnosis of #breastcancer, #colorectalcancer, and #NSCLC. Published in @jamanetworkopen.com and @cancertherapyadv.bsky.social.#breastcancer#colorectalcancer#NSCLChttps://bit.ly/4oVG9RB #bcsm

Ultra-low-pass whole genome sequencing of circulating tumor DNA appears to provide important prognostic information regarding patients with #LBCL. Published in @ascopost.bsky.social JCO Precision Oncology and @hematologyadvisor.bsky.social.#LBCL https://bit.ly/4nzwSO1 #lymsm #lymphoma

#Oncologist coverage across the US has declined in recent years, leading to #caregaps. Published in @ascopost.bsky.social JCO Oncology Practice and @cancertherapyadv.bsky.social.#Oncologist#caregaps https://bit.ly/43dRtjt

Once-weekly subcutaneous marstacimab significantly reduced bleeding rates and was well tolerated in male patients with severe #hemophilia A or moderately severe to severe hemophilia B without inhibitors. Published in @bloodjournals.hematology.org.#hemophilia https://bit.ly/47osaO7

Dr. Anderson of UT Southwestern Medical Center in Dallas, Texas, and the lead clinical investigator for the AURIGA study, sat down with us at #IMS2025 to provide more in-depth information on this study and its clinical significance. https://bit.ly/4hSsrMT #NDMM #MultipleMyeloma

For patients with #sickleCellDisease presenting to an emergency department during a vaso-occlusive crisis, assignment of an appropriate severity level was associated with a shorter TTFA. Reported in @bloodjournals.hematology.org.#sickleCellDisease https://bit.ly/47FABU2 #SCD

Ibrutinib plus rituximab had superior PFS when compared to chemoimmunotherapy among older patients with previously untreated #MCL. Published in @thelancet.com and @cancertherapyadv.bsky.social.#MCL https://bit.ly/48ORgH9 #lymsm

Ibrutinib plus rituximab had superior PFS when compared to chemoimmunotherapy among older patients with previously untreated #MCL. Published in @thelancet.com and @cancertherapyadv.bsky.social.#MCL https://bit.ly/48ORgH9 #lymsm

Researchers developed an ethical framework for allocating gene therapy to patients with #SCD or #TDT. Reported in @bloodjournals.hematology.org.#SCD#TDT https://bit.ly/47uPUPv

CTC levels are an independent prognostic factor for patients with transplant-eligible, #NDMM who were treated with a standard-of-care quadruplet regimen. Published in @bloodjournals.hematology.org and @cancertherapyadv.bsky.social.#NDMM https://bit.ly/4oHqTYd #multipleMyeloma

Younger vs older women are more susceptible to changes to their #menstrual cycle after receiving the #COVID19vaccine. Published in @plosone.org and @infectiousdisease.bsky.social.#menstrual#COVID19vaccine https://bit.ly/47xqnFt

A female patient in her 60s was diagnosed with systemic mastocytosis associated with #PCFCL. Published in @rarediseaseadvisor.bsky.social.#PCFCL https://bit.ly/47O33Ew #lymsm

An elderly man with no prior history of bleeding disorders experienced recurrent acute subdural hematoma following a mild head trauma and was diagnosed with mild congenital #hemophilia A. Published in @cureusmedical.bsky.social and @rarediseaseadvisor.bsky.social.#hemophilia https://bit.ly/3JsRbyy

The combination of PTCy and Aba significantly reduced chronic #GVHD and improved GRFS compared with standard tacrolimus and methotrexate prophylaxis in patients undergoing allo-HSCT. Published in @bloodjournals.hematology.org.#GVHD https://bit.ly/43A8Zys

Among a heavily pretreated, older adult population of patients with R/R NPM1m #AML, revumenib was associated with a clinically meaningful response while retaining a safety profile consistent with previous findings. Published in @bloodjournals.hematology.org.#AML https://bit.ly/4ode7AQ #leusm

Single men with #cancer reported feeling overlooked by their #HCPs. Published in @oncologynurseadv.bsky.social.#cancer#HCPs https://bit.ly/4qocy4w #cancercare

Children in the US will have either relied on publicly subsidized insurance or experienced periods without any insurance during the post-ACA, prepandemic policy era. Recent reductions in #Medicaid funding may worsen existing gaps. From @jama.com @clinicalpainadv.bsky.social.#Medicaid https://bit.ly/4o4svvq

TFR is a feasible target for patients with #CML living in low- and middle-income countries, according to research presented at #ESMO25. https://bit.ly/4727w6m #leusm

Many patients with #CLL/#SLL who were intolerant of ibrutinib and/or acalabrutinib were able to tolerate and benefit from zanubrutinib. Published in @bloodjournals.hematology.org.#CLL#SLL https://bit.ly/4o0q7Wd #leusm

RAS mutations are strong predictors of poor prognosis among adult patients with #myelodysplasticSyndrome. Presented at #ESMO25. https://bit.ly/47i9xdp #MDS

Preliminary results from a phase 2 study suggest that the combination of tislelizumab with chidamide, lenalidomide, and etoposide may be effective for the treatment of R/R ENKTL. Presented at #ESMO25. https://bit.ly/4ovkEGT #lymsm

The arrival of the #Trump administration brought an avalanche of political changes in the US, including within the #healthcare sector, slashing funding for key research programs. https://bit.ly/474ugkS #HemOnc #layoffs

@ash.hematology.org President @b-avalos-md.bsky.social shares her perspectives on the past year’s political changes and how they are affecting #hematology research and care. bit.ly/474ugkS

New insights into #hemophilia A were reported in a study based on an upgrade of a database of unique variants associated with plasma FVIII. https://bit.ly/43vhLh7

The combined use of isatuximab and cemiplimab showed persistent antitumor activity alongside a manageable safety profile among patients with R/R ENKTL. From @hematologyadvisor.bsky.social. https://bit.ly/4qaQavt #lymsm

Efmoroctocog alfa appears to be effective in extended half-life factor VIII replacement and surgical management in patients with #hemophilia A. From @rarediseaseadvisor.bsky.social.#hemophilia https://bit.ly/4o0bIcY

Albuminuria is linked to myriad #cancer risks in adults, independent of eGFR and diabetes, a large study finds. From @renalurologynews.bsky.social.#cancer https://bit.ly/4qdlmtU #cancerrisk

Risk for VTE after an operation for #colorectalcancer is higher among patients with IBD. Published in @gastroadvisor.bsky.social.#colorectalcancer https://bit.ly/47myJAJ #crcsm

Individuals with #hemophilia B without inhibitors do not exhibit an elevated risk for kidney dysfunction or damage compared with the general population. Reported in @rarediseaseadvisor.bsky.social.#hemophilia https://bit.ly/4n248Nr

@ash.hematology.org President Belinda R. Avalos, MD, shares her perspectives on the past year’s political changes and how they are affecting #hematology research and care. https://bit.ly/474ugkS #HemOnc

Teclistamab-based induction regimens have demonstrated efficacy in patients with newly diagnosed #multipleMyeloma. Presented at #IMS2025, covered by @cancertherapyadv.bsky.social.#multipleMyeloma#IMS2025 https://bit.ly/438ADSX

An unusual case has been reported of cold AIHA, of which CAD is a form, evolving to #CLL. Presented at #SOHO2025, covered by @rarediseaseadvisor.bsky.social.#CLL#SOHO2025 https://bit.ly/3KAOF9H #leusm

The pharmacokinetic response of FVIII to desmopressin shows marked interindividual variability among female #hemophilia A carriers. Published in @bloodjournals.hematology.org and @rarediseaseadvisor.bsky.social.#hemophilia https://bit.ly/4nCAMWX

Although #GVHD is a common side effect of blood, marrow, or hematopoietic stem cell transplantation, it can be confusing for patients to understand. https://bit.ly/46IlcTW

CNS involvement occurs in more than 1 in 5 patients with NA-ATLL and is linked to poor survival outcomes. Published in @ascopost.bsky.social. https://bit.ly/4o0rjso #lymsm #leusm

CNS involvement occurs in more than 1 in 5 patients with NA-ATLL and is linked to poor survival outcomes. Published in @ascocancer.bsky.social journal JCO Precision Oncology. https://bit.ly/4o0rjso

Certain cancers and #cancertreatments are associated with lower live birth rates and higher risk for obstetric and neonatal adverse outcomes. Published in @endocrinologyadv.bsky.social.#cancertreatments https://bit.ly/4764Lkj